Radiation plus lurbinectedin for advanced small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies whether adding palliative (comfort-focused) radiation to the medicine lurbinectedin can better control extensive-stage small cell lung cancer. It may help reduce problems from tumors in places like bones and organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older
- Have extensive-stage small cell lung cancer confirmed by biopsy
- Be able to do usual daily activities to a limited degree (ECOG 0–3)
- Have tumors in bone or other internal organs/lungs seen on scans within the last 90 days
- Be able to take lurbinectedin (either already on it or your doctor thinks it fits after prior treatment)
- Have blood test levels that are safe (enough white blood cells, platelets, and hemoglobin)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial adds total body irradiation (a low dose of radiation to the whole body) to standard atezolizumab (immunotherapy) plus chemotherapy for people with extensive-stage small cell lung cancer. The goal is to see if the radiation helps the immunotherapy work better.
This trial tests a combination of an immunotherapy drug (adebrelimab), chemotherapy, and radiation therapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if this combination helps people live longer and feel better.
This trial tests a combination of two drugs—lurbinectedin and durvalumab—for people with extensive-stage small cell lung cancer who have already received initial treatment. The goal is to see if this combination can help control the cancer better.
This trial tests whether adding lurbinectedin to paclitaxel (a standard chemo drug) helps people with small cell lung cancer that has progressed after prior treatment. You would receive either the combination or paclitaxel alone, and the study compares how well each works.
This trial compares a new drug combination (lurbinectedin with or without irinotecan) against the standard treatment (topotecan) for people whose small cell lung cancer has come back after initial chemotherapy. It aims to see if the new options work better.
This trial tests a combination of two drugs, lurbinectedin and serplulimab, as maintenance therapy after initial chemotherapy for people with extensive-stage small cell lung cancer (SCLC) that hasn't spread to the brain. The goal is to see if this approach helps keep the cancer from growing for longer.
Hear when a new Extensive Stage Lung Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.